You are here

Strategies for Immune Tolerance and Immune Evasion

The wider accessibility of cell and tissue therapies will require the success of off‐the‐shelf, allogeneic products that can be administered to patients regardless of immune compatibility with the donor tissue. Critically, we must develop alternative methods to overcome immune barriers to engraftment, as long‐term use of immunosuppressive drugs renders patients subject to infectious disease and other side effects. The California Institute for Regenerative Medicine (CIRM) has funded multiple programs in different disease areas and at various stages of therapeutic development that aim to tackle this challenge. Now, Lisa C. Kadyk (CIRM, Oakland, California, USA) and colleagues summarize the main approaches taken in this rapidly moving field and provide examples of specific programs that the CIRM has funded. For a fascinating read, head over to STEM CELLS Translational Medicine now!